-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FT-819 in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FT-819 in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FT-819 in B-Cell Acute Lymphocytic...
-
Sector Analysis
NewData Centers 2.0 – Transforming Tomorrow’s Compute
As the digital landscape evolves, the role and design of data centers are undergoing a profound transformation. "Data Centers 2.0: Transforming Tomorrow's Compute" illuminates the cutting-edge technologies and innovations redefining this space. Central to this transformation is the integration of advanced network services virtualization, grid computing, and hybrid cloud management, alongside pioneering cooling systems and power management solutions. These advancements not only enhance the efficiency and scalability of data centers but also address the increasing environmental concerns associated with their...
-
Sector Analysis
NewInternet from Sky – Can LEO Satellites Transform the Future of Connectivity? (Vol. 2)
LEO Satellites - Internet from Sky Report Overview The surge in low earth orbit (LEO) satellite projects indicates a global trend toward diversifying internet coverage. This trend focuses on bridging the digital divide and enhancing real-time data transmission for various sectors, including aerospace and defense. LEOs provide a competitive edge due to their lower latency, and their increasing deployment signifies a pivotal shift toward a more connected future. LEOs are more secure than terrestrial networks as communication happens in space...
-
Product Insights
NewNet Present Value Model: Fate Therapeutics Inc’s FT-538
Empower your strategies with our Net Present Value Model: Fate Therapeutics Inc's FT-538 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Fate Therapeutics Inc’s FT-596
Empower your strategies with our Net Present Value Model: Fate Therapeutics Inc's FT-596 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Fate Therapeutics Inc’s FT-516
Empower your strategies with our Net Present Value Model: Fate Therapeutics Inc's FT-516 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Forma Therapeutics Inc’s FT-7051
Empower your strategies with our Net Present Value Model: Forma Therapeutics Inc's FT-7051 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Rebyota in Crohn’s Disease (Regional Enteritis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rebyota in Crohn's Disease (Regional Enteritis) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rebyota in Crohn's Disease (Regional Enteritis) Drug Details: Fecal microbiota,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AMY-109 in Endometriosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AMY-109 in Endometriosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AMY-109 in Endometriosis Drug Details: AMY-109 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CGX-1321 in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CGX-1321 in Pancreatic Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CGX-1321 in Pancreatic Cancer Drug Details: CGX-1321 is under development for the...